Company news

GSK plc news in 2026

GSK plc's news releases, calls and decks from 2026, newest first.

View company

Notice of AGM 2026

March 25, 2026

Admission to Trading

March 23, 2026

GSK Lung Cancer ADC Gets Japan Orphan Drug Status

March 23, 2026

Lynavoy (linerixibat) approved by US FDA

March 19, 2026

US FDA approves Arexvy for adults 18-49 AIR

March 13, 2026

Board Committee Change

March 9, 2026

GSK and Alfasigma agree global linerixibat rights

March 9, 2026

Filing of GSK plc 2025 Annual Report on Form 20-F

March 6, 2026

GSK publishes Annual Report 2025

March 5, 2026

GSK completes acquisition of RAPT Therapeutics

March 3, 2026

Total Voting Rights

March 2, 2026

Linerixibat accepted for priority review in China

February 26, 2026

Bepirovirsen accepted for Japan regulatory review

February 26, 2026

GSK enters agreement to acquire 35Pharma

February 25, 2026

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

February 23, 2026

GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

February 18, 2026

GSK - fourth tranche of share buyback programme

February 17, 2026

Exdensur approved by the European Commission

February 17, 2026

China CDE accepts Arexvy adults 60+ application

February 10, 2026

Director/PDMR Shareholding

February 9, 2026

Nucala COPD approved by the European Commission

February 6, 2026

Final Results

February 4, 2026

European Commission approves Arexvy for adults 18+

January 26, 2026

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

January 21, 2026

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

January 20, 2026

GSK to acquire RAPT Therapeutics

January 20, 2026

Agreement on changes to ViiV minority shareholding

January 20, 2026

EC approval of Shingrix PFS

January 7, 2026

Positive phase 3 data for GSK's bepirovirsen

January 7, 2026

Exdensur approved in Japan

January 6, 2026

Nucala for adults with COPD approved in China

January 5, 2026

← Newer news releases

Calls in 2026

Decks in 2026